Tradestie Institutional Equity Comparison Engine

QGRD vs ABUS โ€” Head-to-Head Terminal

6-dimension institutional benchmarking across valuation, multi-year operating margins, normalized momentum, and dealer gamma corridors.

Market Close: 2026-11-16 Buy Verdict Report Ask Alpha

Pillar 1 Executive Scorecard & Category Winner Tally

ABUS Overall Edge

ABUS Captures Institutional Edge (3โ€“1 Pillars ยท 8โ€“2 Matrix Metrics)

Tradestie Institutional Equity Comparison Engine assigns the overall head-to-head edge to Arbutus Biopharma Corporation Common Stock (ABUS) driven by superior Valuation, Growth & Margin, Options & Structure while QGRD counters with relative strength in Momentum & Technical. Fundamentally, QGRD trades at N/M Forward P/E with N/A operating margin (N/A YoY revenue) versus ABUS at 10.2x Forward P/E and 80.1% operating margin (-43.5% YoY). In options structure, QGRD sits in UNCLASSIFIED (N/A IV; Dealer Gamma Walls on Pro) against ABUS sits in CONSOLIDATION (28th %ile IV; Dealer Gamma Walls on Pro).

Valuation Winner ABUS
QGRD N/M vs ABUS 10.2x Fwd P/E
Growth & Margin Winner ABUS
Op Margin N/A vs 80.1% ยท YoY N/A vs -43.5%
Momentum & Technical Winner QGRD
1Y +1.7% vs -11.4% ยท 52W Pos 54% vs 28%
Options & Structure Winner ABUS
UNCLASSIFIED (N/A IV) vs CONSOLIDATION (28th %ile IV)
QGRD NASDAQ
Horizon Nasdaq-100 Defined Risk ETF
Institutional Equity
$27.58
-1.28% 1D
Market Cap N/A
1M Return -4.76%
1Y Return +1.66%
Forward P/E N/M
Unified AI Score
54.7 / 100 HOLD
Tech 53.0 Fund 64.0 Flow 50.0 Mom 64.0
ABUS NASDAQ
Arbutus Biopharma Corporation Common Stock
Pharmaceutical Preparations
$4.04
-1.22% 1D
Market Cap $627.0M
1M Return -4.27%
1Y Return -11.4%
Forward P/E 10.2x
Unified AI Score
56.3 / 100 HOLD
Tech 72.0 Fund 65.0 Flow 68.0 Mom 53.7

Pillar 2 Normalized Relative Return Performance (% Indexed to 0%)

1Y Indexed Return: QGRD +1.66% ABUS -11.4% Spread: +13.06 pp (QGRD Lead)

Pillar 3 Operating Profitability Benchmark (Trailing 12-Month)

Split-Invariant Revenue ($B) & Operating Margin (%)
QGRD TTM Op. Margin: N/A ABUS TTM Op. Margin: 80.1%
Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on QGRD vs ABUS. Trailing 12-month operating profitability (QGRD N/A vs ABUS 80.1%) and valuation multiples (QGRD N/M vs ABUS 10.2x Forward P/E) are benchmarked directly in Pillar 4 below.

Pillar 4 Head-to-Head Fundamental & Valuation Matrix

Matrix Tally: QGRD (2) vs ABUS (8)
Institutional Metric QGRD ABUS Criterion Row Winner
Market Capitalization Scale N/A $627.0M Larger Scale ABUS
Trailing P/E Ratio Valuation N/M 3.6x Lower Multiple ABUS
Forward P/E Ratio Valuation N/M 10.2x Lower Multiple ABUS
Revenue Growth (YoY) Growth N/A -43.5% Higher Growth ABUS
Operating Margin (TTM) Profitability N/A 80.1% Higher Margin ABUS
Net Profit Margin Profitability N/A 121.2% Higher Margin ABUS
Return on Equity (ROE) Capital Efficiency N/A 269.6% Higher ROE ABUS
52-Week Range Position Momentum 54% ($24โ€“$31) 28% ($4โ€“$5) Stronger Trend QGRD
Beta / 30D Volatility Risk Regime 1.00ฮฒ ยท 21% Vol 1.20ฮฒ ยท 51% Vol Lower Realized Risk QGRD
Unified Institutional Score Composite Signal 54.7 / 100 (HOLD) 56.3 / 100 (HOLD) Higher Composite ABUS

Pillar 5 Options Structure, IV Regime & Dealer Gamma Corridor

Full QGRD vs ABUS Buy Guide
QGRD UNCLASSIFIED
0d in phase ยท OBV NEUTRAL
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
IV Percentile N/A
IV Regime Unclassified
Live QGRD Put/Call Gamma Walls & dealer positioning signals require Pro. Unlock 14-Day Free Trial →
ABUS CONSOLIDATION
92d in phase ยท OBV ACCUMULATION
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
IV Percentile 28th %ile
IV Regime Balanced (25thโ€“60th %ile)
Live ABUS Put/Call Gamma Walls & dealer positioning signals require Pro. Unlock 14-Day Free Trial →

Pillar 6 90-Day Technical & R&D Innovation Disclosures

Corporate R&D & Foundry Tracker
Neither QGRD nor ABUS registered frontier semiconductor/AI engineering publications in the trailing 90-day window; head-to-head edge is anchored on operating margin trajectory, valuation multiples, and options structure above.